Form 4: Equillium Director Charles Douglas McDermott Granted 20,000 Stock Options

Equillium, Inc. Director Charles Douglas McDermott was granted 20,000 stock options with an exercise price of $0.39, aligning his interests with shareholders.

Summary

• Equillium, Inc. (EQ) Director Charles Douglas McDermott was granted 20,000 Director Stock Options.
• The options have an exercise price of $0.39 per share.
• The grant date for these options was May 21, 2025.
• The options vest in twelve equal monthly installments commencing on the grant date.
• The options will be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
• The expiration date for these options is May 20, 2035.
• Following this transaction, Mr. McDermott beneficially owns 20,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard practice that aligns management's interests with shareholders, indicating continued commitment and incentivizing long-term performance. It is not a major market-moving event but reflects healthy corporate governance practices.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $0.39 is set, providing a clear benchmark for potential future value.

Future Outlook

The stock options granted to Director Charles Douglas McDermott are subject to a vesting schedule, with options vesting in twelve equal monthly installments commencing on the grant date of May 21, 2025, and fully vesting by the date of the Issuer's annual meeting of stockholders following the grant date. This indicates a future alignment of the director's compensation with the company's performance over the vesting period.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like Equillium, Inc. This form of compensation is widely used to attract, retain, and incentivize key personnel by linking their financial success directly to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard component of executive and director compensation packages across various industries, including biotechnology.
• The vesting schedule (12 equal monthly installments, with full vesting by the next annual meeting) is a common structure designed to ensure continued commitment and performance over a defined period.
• The exercise price being set at a specific value ($0.39) is typical for compensatory option grants, often reflecting the stock price at or near the grant date, though the document does not specify the stock price on the grant date.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Charles Douglas McDermott constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Director (Charles Douglas McDermott): Receives equity-based compensation, incentivizing his continued service and contribution to the company's success.

Next Steps

• The options will vest in twelve equal monthly installments commencing on May 21, 2025.
• The options will be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Key Dates

Keywords

Equillium, EQ, stock options, director compensation, insider transaction, equity grant, Form 4, beneficial ownership